GW&K Investment Management LLC Has $52.43 Million Stake in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)

GW&K Investment Management LLC grew its stake in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVNGet Rating) by 389.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 380,437 shares of the company’s stock after acquiring an additional 302,679 shares during the period. GW&K Investment Management LLC owned 0.58% of Biohaven Pharmaceutical worth $52,428,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. National Bank of Canada FI acquired a new position in Biohaven Pharmaceutical during the fourth quarter valued at approximately $28,000. Harbor Investment Advisory LLC raised its holdings in shares of Biohaven Pharmaceutical by 25.4% in the 4th quarter. Harbor Investment Advisory LLC now owns 587 shares of the company’s stock worth $81,000 after acquiring an additional 119 shares during the last quarter. Montag A & Associates Inc. increased its stake in Biohaven Pharmaceutical by 16.7% in the 4th quarter. Montag A & Associates Inc. now owns 804 shares of the company’s stock valued at $111,000 after buying an additional 115 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Biohaven Pharmaceutical by 9.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 808 shares of the company’s stock valued at $112,000 after acquiring an additional 72 shares during the period. Finally, Lindbrook Capital LLC bought a new position in Biohaven Pharmaceutical in the 4th quarter worth approximately $113,000. Institutional investors own 88.03% of the company’s stock.

Shares of NYSE BHVN traded up $0.98 during mid-day trading on Friday, hitting $142.03. 2,414,739 shares of the company were exchanged, compared to its average volume of 3,415,891. The stock has a 50 day simple moving average of $115.91 and a 200-day simple moving average of $121.16. Biohaven Pharmaceutical Holding Company Ltd. has a 1-year low of $75.38 and a 1-year high of $151.51. The firm has a market cap of $10.02 billion, a price-to-earnings ratio of -12.00 and a beta of 1.20.

Biohaven Pharmaceutical (NYSE:BHVNGet Rating) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($2.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.45). During the same quarter last year, the firm posted ($4.21) earnings per share. On average, equities analysts anticipate that Biohaven Pharmaceutical Holding Company Ltd. will post -9.85 EPS for the current year.

In other Biohaven Pharmaceutical news, CAO George C. Clark sold 4,200 shares of the firm’s stock in a transaction dated Tuesday, May 10th. The stock was sold at an average price of $141.50, for a total value of $594,300.00. Following the sale, the chief accounting officer now directly owns 4,065 shares of the company’s stock, valued at approximately $575,197.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 12.40% of the stock is owned by company insiders.

A number of equities analysts recently commented on the stock. Mizuho lifted their target price on shares of Biohaven Pharmaceutical from $144.00 to $154.00 and gave the stock a “buy” rating in a research report on Thursday, March 3rd. SVB Leerink cut shares of Biohaven Pharmaceutical from an “outperform” rating to a “market perform” rating and set a $150.00 target price for the company. in a report on Wednesday, May 11th. Morgan Stanley decreased their price objective on shares of Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. HC Wainwright cut shares of Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating in a report on Wednesday, May 11th. Finally, Cantor Fitzgerald lowered shares of Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating in a research report on Wednesday, May 11th. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $152.36.

Biohaven Pharmaceutical Company Profile (Get Rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

See Also

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVNGet Rating).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.